Mouse CD70 / CD27L / TNFSF7 Protein (Fc Tag)

Cd27l,CD27LG,Tnfsf7

• 100ug (NPP3410) Please inquiry

Catalog Number	P51129-M04H
Organism Species	Mouse
Host	Human Cells
Synonyms	Cd27l,CD27LG,Tnfsf7
Molecular Weight	The recombinant mouse Cd70 consists 385 amino acids and predicts a molecular mass of 43.1 kDa.
predicted N	Asp
SDS-PAGE
Purity	> (12.5+86.3) % as determined by SDS-PAGE.
Protein Construction	A DNA sequence encoding the mouse Cd70 (NP_035747.1) (Gln47-Pro159) was expressed with the Fc region of mouse IgG1 at the N-terminus.
Bio-activity
Research Area	Cancer |Invasion microenvironment |Angiogenesis |Cytokines / Chemokines in Angiogenesis |TNF
Formulation	Lyophilized from sterile PBS, pH 7.4. 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.
Reference	Adam PJ, et al. (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer. 95(3): 298-306. Keller AM, et al. (2007) Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proc Natl Acad Sci U S A. 104(14): 5989-94. Grewal IS. (2008) CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 12(3): 341-51. Boursalian TE, et al. (2009) Targeting CD70 for human therapeutic use. Adv Exp Med Biol. 647: 108-19.